MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
Genfit S.A. (NASDAQ:GNFT)(OTCPK:GNFTF
Organization & Developments: Genfit
Parents
Genfit S.A. (NASDAQ:GNFT)(OTCPK:GNFTF
Children
2017: French based biopharma focusing on developing therapeutic and diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases with a focus on the liver and gastroenterology
2017: Genfit up 23% on rumored Novartis interest - Genfit (OTCMKTS:GNFTF)
2017: The company is developing a variety of biomarkers, but the main asset is the company's primary drug candidate Elafibranor, also known as GFT505.
2017: The company is hoping to show that Elafibranor reverses nonalcoholic steatohepatitis {NASH} to prevent fibrosis progression.
2018: Genfit Announces Positive Data For Chronic Liver Disease Using Its NASH Drug_seekingalpha.com
2018: Genfit: Valuing Elafibranor's Commercial Potential_seekingalpha.com
2018: Genfit: Why Is This One Of The Most Promising Players In NASH?_seekingalpha.com
2018: The Science Behind Genfit's Elafibranor - Genfit (OTCMKTS:GNFTF)
2019: 8 programs to watch in NASH: Four letters and a multibillion-dollar opportunity
2019: Biotech Analysis Central Preview Series: Genfit_seekingalpha.com
2019: Genfit Breakthrough Therapy Designation Based On Impressive Data_seekingalpha.com
2019: Genfit goes to China with a deal worth up to $228M for NASH drug – Endpoints News
2020: Genfit prunes nearly half its workforce after NASH exit — but CEO promises a future in PBC, diagnostics_endpts
2020: Genfit throws in the towel on NASH, exiting a tumultuous field full of bright market prospects and lethal R&D setbacks – Endpoints News
2020: Genfit’s NASH drug fails a closely-watched PhIII showdown, adding one more setback to a plagued field – Endpoints News
2021: Taking A Gander At Genfit
2022: A Long Wait For Genfit May Be Worth It_ seekingalpha.com
2022: Genfit S.A.: A 'Sum Of The Parts' Story_seekingalpha.com
2023: Genfit: Large PBC Market, Liquidity To Await Approval_ seekingalpha.com
Jumps
*Key People: Genfit
Finance & Acquisitions: Genfit